Abstracts tagged "Kawasaki disease and polymorphism"

Abstract Number: 178 • 2013 ACR/ARHP Annual Meeting
Fc-Gamma Receptor Genetic Variation In Kawasaki Disease
Carline E. Tacke^1,2, Willemijn B. Breunis^3,4, Long T. Hoang¹, Eileen Png¹, Judy Geissler⁵, Sietse Nagelkerke⁴, Justine Ellis^6,7, Sonia Davila⁸, Chiea Chuen Khor⁸, Michael Levin⁹, David Burgner^10,11, Chisato Shimizu¹², Jane C. Burns¹², Martin L. Hibberd¹ and Taco W. Kuijpers^4,13, ¹Infectious Diseases, Genome Institute of Singapore, Singapore, Singapore, ²Pediatric Hematology, Immunology and Infectious Diseases, Emma Children's Hospital/Academic Medical Center (AMC), Amsterdam, Netherlands, ³Pediatric rheumatology and immunology, Emma Children's Hospital/Academic Medical Center (AMC), Amsterdam, Netherlands, ⁴Blood cell research, Sanquin Resarch and Landsteiner Laboratory (AMC), Amsterdam, Netherlands, ⁵Sanquin Resarch and Landsteiner Laboratory (AMC), Amsterdam, Netherlands, ⁶Murdoch Childrens Research Institute, Parkville, Australia, ⁷Department of Paediatrics, The University of Melbourne, Parkville, Australia, ⁸Human Genetics, Genome Institute of Singapore, Singapore, Singapore, ⁹Department of Pediatrics, Imperial College London, London, United Kingdom, ¹⁰The royal Children's Hospital, Murdoch Childrens Research Institute, Parkville, Australia, ¹¹Department of Paediatrics, The University of Melbourne, Melbourne, Australia, ¹²Pediatrics, UC San Diego, School of Medicine, La Jolla, CA, ¹³Pediatric Rheumatology and Immunology, Emma Children's Hospital/Academic Medical Center (AMC), Amsterdam, Netherlands
Abstract on behalf of the International Kawasaki Disease Genetics Consortium. Background/Purpose: Kawasaki disease (KD) is a pediatric vasculitis of unknown etiology with a substantial genetic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].